BIOPHARMA
ByEndpoints Signal Report Finds Nearly Half of Biopharma Professionals Are Heavy AI Users, With Expectations of Major R&D Transformation Ahead
Based on Endpoints Signal Pulse Report | December 2025 A new Signal Pulse Report from Endpoints News reveals…
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
PhaseV Reports Breakthrough Year in 2025, Marking Transition to Scaled AI Deployment in Clinical Development
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
Takeda Announces Positive Phase III Results for AI-Discovered Oral Psoriasis Therapy
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
